Phase 2 N=36 Phase II Sunitinib Prog Met AIPC
Metastatic Prostate Cancer
Primary: Median Progression-free Survival (PFS) Time at 1-year. — 19.4 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model
Dental Erosion
Primary: Percentage Surface Micro-hardness Recovery (SMHR) of Enamel Specimens — 39.46; 38.31; 36.17; 17.26 % SMHR — p=0.7756
Phase 2 N=24 Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Mucosal Melanoma · Acral/Lentiginous Melanoma · Chronically Sun Damaged Melanomas
Primary: Best Overall Response — 0; 0; 0; 7 participants
Phase 2 N=64 A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease · COPD
Primary: Weighted Mean (0-24hr) Change From Baseline FEV1 (Forced Expiratory Volume in 1 Second) — -14.4; 90.2; 98.5 mL
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Phase 2 N=72 The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients
Fatigue
Primary: The Lee Fatigue Scale — 3.71; 3.68; 3.9; 5.32 units on a scale
Phase 2 N=275 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
Phase 2 N=139 Effect of OC000459 on Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Eczema Area and Severity Index (EASI) Compared to Placebo at Week 16 — -3.8; -6.1 units on a scale
Phase 2 N=136 Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Sarcoma
Primary: Progression Free Survival — 186; 271 Days
Phase 2 N=354 A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second) — -32.4; 19.4; 155.0; 134.2 mL
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 2 N=145 Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
Type 1 Diabetes Mellitus
Primary: The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit — 0.448; 0.350; 0.418 nmol/L — p=0.98
Phase 2 N=205 Remote Ischemic Preconditioning Prior to Vascular Surgery
Peripheral Arterial Disease · Vascular Surgery
Primary: Troponin I Elevation Above the Upper Reference Limit (URL) — 25; 22 participants
Phase 2 N=21 Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects
Obesity
Primary: Steady-State AUC of Oseltamivir Carboxylate — 2579 hour*ng/mL
Phase 2 N=140 Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
Parkinson Disease · Neurodegenerative Diseases · Central Nervous System Diseases
Primary: Number of Participants Who Experienced at Least One Adverse Event — 123 Participants